Fundraising FoxLilly Asia Ventures — 2020 Investments
5 investments dated 2020 · listed companies and verified rows first · show all
ADARx is a clinical-stage biotechnology company developing RNA-targeted therapeutics designed to control the expression of disease-driving genes.
BiotechHealthtechMedical DevicesSan Diego, US
Zhen Li(Co-founder, President & CEO)inRui Zhu(Founding Member & Chief Technology Officer)Rob Ackles(Chief People Officer)inRyan Fisk(Chief Financial Officer & Chief Business Officer)inRobert A. MacLeod(Chief Scientific Officer)inChristopher Claeboe(Senior Vice President of Operations)in
Board seatHongbo Lu· per SEC Form D
Co-investorsBain Capital Life SciencesOrbiMedSR One Capital ManagementT. Rowe PriceAscenta CapitalTCG Crossover+3 more
Perfuse Therapeutics develops novel ocular therapies for retinal and glaucoma diseases through drug delivery and formulation platforms.
BiotechHealthtechMedical DevicesSan Francisco, US
Sevgi Gurkan(Founder, Chief Executive Officer, and Member of the Board of Directors)in
BoardChristy Shaffer(Director)Chau Khuong(Director)in
Board seatHongbo Lu· per SEC Form D
Co-investorsOrbiMedAccess BiotechnologyCatalio Capital Management, LPHatteras Venture PartnersLAVHatteras
Rgenta develops orally available small molecule therapies that target RNA to address diseases previously considered undruggable, with programs in oncology (targeting proteins such as MYB in solid tumors and hematologic cancers) and central nervous system repeat expansion disorders like Huntington's disease.
AI & Machine LearningBiotechDeep TechHealthtechCambridge, US
Travis Wager(Co-founder, President and CSO)inHualin Simon Xi(Executive Officer, Director)Zhiping Weng(Co-founder)inSimon Xi(Co-founder and CEO)inJackie Walling(CMO)Debasish Roychowdhury(Director)
Board seatHongbo Lu· per SEC Form D · $38M raise · filed Mar 2021
Co-investorsDelos CapitalVivo CapitalAMR Action FundBoehringer Ingelheim Venture FundKorea Investment PartnersMatrix Capital Management+1 more
Terns Pharmaceuticals is a biopharmaceutical company developing therapies, including its TERN-701 program.
BiotechHealthtechFoster City, US
Mark Vignola, Ph.D.(Executive Officer)Bryan Yoon(Executive Officer)inSenthil Sundaram(Director, Executive Officer)inWeidong Zhong, Ph.D.(Executive Officer, Director)Jill Quigley(Director)inDavid Fellows(Director)
PartnerHongbo Lu· solo GP
Co-investorsDecheng CapitalLAVVivo Capital
Hong Kong-listed, Suzhou-headquartered biopharmaceutical company developing antibody therapeutics with in-house biomanufacturing.
Suzhou, CN
Xueming Qian(Executive Director, Chairman and CEO)in
Co-investorsARCH Venture PartnersChina Structural Reform FundFortune Venture CapitalHillhouse CapitalQatar Investment AuthorityTemasek
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.